B. Riley Securities maintains Novavax at Buy, lowers price target to $16 from $18

B. Riley Securities kept its Buy rating on Novavax but reduced its price target from $18 to $16, an 11.1% cut. The new target suggests a 63.6% upside from the Nov 5 closing price of $9.78.

Original reporting
Published Nov 6, 2026, 3:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B. Riley Securities maintains Novavax at Buy, lowers price target to $16 from $18 — source image
Decision brief

The 30-second read

$NVAXBearishMed
01

Why it matters

The downgrade reflects B. Riley's revised outlook, which could trigger short‑term selling but may be mitigated by upcoming clinical data.

02

Market read

A fresh analyst downgrade provides a timely signal for traders to reassess NVAX positions.

03

What to watch

Potential upcoming data releases or partnership news could offset the downgrade.

Relevance 5/10Novelty 6/10Timing: immediate

Background

Novavax is a US‑listed biotech focused on vaccine development. Analyst price‑target adjustments are common after earnings or pipeline updates.

Company-level read

Ticker impact

$NVAXBearishMedium confidence
Context

B. Riley lowered Novavax's price target to $16 from $18, indicating a fresh downgrade.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

The new target is 11% lower than the prior one, a material change that can prompt sell‑offs.

Market effects

May weigh on other biotech stocks as analysts tighten targets.

Limited to US biotech sector.

Low

Counterpoint

Some investors may view the lower target as an opportunity if they believe the market overreacted.

Key entities

  • Novavax

    Vaccine developer (ticker NVAX).

  • B. Riley Securities

    Equity research firm issuing the rating change.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.